Lexicon Pharmaceuticals (LXRX) : Falcon Point Capital scooped up 9,816 additional shares in Lexicon Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 287,809 shares of Lexicon Pharmaceuticals which is valued at $4,668,262.Lexicon Pharmaceuticals makes up approximately 0.78% of Falcon Point Capital’s portfolio.
Other Hedge Funds, Including , American Century Companies Inc added LXRX to its portfolio by purchasing 152,914 company shares during the most recent quarter which is valued at $2,480,265. Stoneridge Investment Partners sold out all of its stake in LXRX during the most recent quarter. The investment firm sold 43,948 shares of LXRX which is valued $712,837. Acadian Asset Management added LXRX to its portfolio by purchasing 60,136 company shares during the most recent quarter which is valued at $917,074.Cutler Group Lp reduced its stake in LXRX by selling 7,115 shares or 22.27% in the most recent quarter. The Hedge Fund company now holds 24,837 shares of LXRX which is valued at $359,888. Lexicon Pharmaceuticals makes up approx 0.02% of Cutler Group Lp’s portfolio.
Lexicon Pharmaceuticals closed down -0.14 points or -0.85% at $16.32 with 4,42,681 shares getting traded on Friday. Post opening the session at $16.39, the shares hit an intraday low of $16.21 and an intraday high of $16.46 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Lexicon Pharmaceuticals reported $-0.34 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $-0.30. The company had revenue of $12.50 million for the quarter, compared to analysts expectations of $11.11 million. The company’s revenue was up 594.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.04 EPS.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.